Compare Stocks → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABOSNASDAQ:CLLSNASDAQ:DBVTNASDAQ:MGTXNASDAQ:PASG Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$3.17-0.6%$3.86$1.81▼$11.31$190.45M0.08372,111 shs140,589 shsCLLSCellectis$2.51+0.8%$2.62$0.96▼$3.77$139.26M3.1242,654 shs223,279 shsDBVTDBV Technologies$0.68-1.4%$0.77$0.65▼$2.37$131.54M0.7550,065 shs41,558 shsMGTXMeiraGTx$4.80+1.9%$5.82$3.49▼$8.35$308.26M1.29153,273 shs74,543 shsPASGPassage Bio$1.32+8.2%$1.38$0.58▼$1.79$81.33M1.3349,499 shs75,711 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals+0.31%+0.95%-14.93%-1.54%-15.16%CLLSCellectis-0.40%+0.81%-0.40%-16.16%+30.37%DBVTDBV Technologies+3.68%-0.09%-11.19%-22.97%-56.64%MGTXMeiraGTx-3.09%-5.99%-23.54%-30.22%-12.45%PASGPassage Bio-1.61%+1.67%-3.94%+25.77%+28.22%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABOSAcumen Pharmaceuticals3.1427 of 5 stars3.55.00.00.02.81.70.6CLLSCellectis2.4489 of 5 stars3.52.00.00.01.52.51.3DBVTDBV Technologies2.227 of 5 stars3.23.00.00.00.03.31.3MGTXMeiraGTx4.2526 of 5 stars3.53.00.04.82.51.70.6PASGPassage Bio2.527 of 5 stars3.52.00.00.01.82.51.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals3.00Buy$12.25286.44% UpsideCLLSCellectis3.00Buy$8.50239.24% UpsideDBVTDBV Technologies2.33Hold$5.00633.14% UpsideMGTXMeiraGTx3.00Buy$25.67434.72% UpsidePASGPassage Bio3.00Buy$9.33607.07% UpsideCurrent Analyst RatingsLatest CLLS, DBVT, PASG, MGTX, and ABOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024ABOSAcumen PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.003/15/2024MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.003/5/2024PASGPassage BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.002/21/2024DBVTDBV TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$4.61 per shareN/ACLLSCellectis$25.73M5.41N/AN/A$2.76 per share0.91DBVTDBV Technologies$15.73M8.36N/AN/A$0.73 per share0.93MGTXMeiraGTx$14.02M21.99N/AN/A$2.17 per share2.21PASGPassage BioN/AN/AN/AN/A$2.03 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$52.37M-$1.09N/AN/AN/AN/A-23.40%-21.78%5/14/2024 (Estimated)CLLSCellectis-$106.14M-$1.67N/AN/AN/A-346.65%-73.03%-32.22%5/2/2024 (Estimated)DBVTDBV Technologies-$72.73M-$0.39N/AN/AN/A-461.32%-46.33%-35.32%5/2/2024 (Estimated)MGTXMeiraGTx-$84.03M-$1.47N/A5.33N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)PASGPassage Bio-$102.06M-$1.86N/AN/AN/AN/A-73.12%-56.17%5/9/2024 (Estimated)Latest CLLS, DBVT, PASG, MGTX, and ABOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023ABOSAcumen Pharmaceuticals-$0.29-$0.29N/A-$0.29N/AN/A3/14/2024Q4 2023MGTXMeiraGTx-$0.46-$0.47-$0.01-$1.36$10.13 million$2.04 million3/7/2024Q4 2023DBVTDBV Technologies-$0.16-$0.06+$0.10-$0.06$1.10 million$8.88 million 3/4/2024Q4 2023PASGPassage Bio-$0.41-$0.30+$0.11-$0.30N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.1119.0119.01CLLSCellectis0.572.202.20DBVTDBV TechnologiesN/A4.264.26MGTXMeiraGTx0.622.382.38PASGPassage BioN/A7.227.22OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%CLLSCellectis63.90%DBVTDBV Technologies71.74%MGTXMeiraGTx67.48%PASGPassage Bio53.48%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals7.50%CLLSCellectis16.41%DBVTDBV Technologies0.71%MGTXMeiraGTx9.70%PASGPassage Bio12.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals3960.08 million55.57 millionOptionableCLLSCellectis23155.58 million46.46 millionOptionableDBVTDBV Technologies104192.87 million191.50 millionOptionableMGTXMeiraGTx41964.22 million57.99 millionOptionablePASGPassage Bio5861.61 million53.97 millionOptionableCLLS, DBVT, PASG, MGTX, and ABOS HeadlinesSourceHeadlineContrasting Passage Bio (NASDAQ:PASG) and Scholar Rock (NASDAQ:SRRK)americanbankingnews.com - April 26 at 1:40 AMPassage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summitfinance.yahoo.com - April 22 at 10:03 AMPassage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summitglobenewswire.com - April 22 at 7:00 AMPassage Bio (NASDAQ:PASG) Stock Price Down 5.5%americanbankingnews.com - April 19 at 2:22 AMPassage Bio (NASDAQ:PASG) Trading Up 3.1%marketbeat.com - March 29 at 12:36 AMPASG Apr 2024 7.500 callfinance.yahoo.com - March 20 at 5:43 AMPASG Apr 2024 5.000 callfinance.yahoo.com - March 16 at 9:42 AMPassage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Knowzacks.com - March 7 at 1:01 PMPASG Stock Earnings: Passage Bio Beats EPS for Q4 2023investorplace.com - March 6 at 3:01 PMPassage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Programfinance.yahoo.com - March 5 at 9:05 AMPassage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlightsglobenewswire.com - March 4 at 7:00 AMPassage Bio to Showcase Advancements at Major Health Care Conferencesmsn.com - March 3 at 7:54 PMPassage Bio to Participate in Upcoming Investor Conferencesglobenewswire.com - February 27 at 7:00 AMPassage Bio Inc (PASG)investing.com - February 20 at 9:10 PMPASG/USD - Passage US Dollarinvesting.com - February 16 at 8:20 AMWe Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefullyfinance.yahoo.com - February 12 at 2:07 PMPassage Bio CEO to Address Guggenheim Healthcare Talks 6th Annual Biotechnology Conferencemsn.com - February 2 at 7:34 AMPassage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conferencefinance.yahoo.com - January 31 at 8:18 AMPassage Bio Stock (NASDAQ:PASG) Dividends: History, Yield and Datesbenzinga.com - December 21 at 5:54 PMPassage looks to offload lead program, 2 other clinical-stage assetsfiercebiotech.com - December 20 at 2:47 PMNeurology-Focused Passage Bio Reveals Initial Data From Dementia Study, Outlines Strategic Prioritiesmsn.com - December 20 at 2:47 PMPassage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN ...bakersfield.com - December 20 at 9:47 AMPassage Bio Announces Initial Clinical Data From Phase 1/2 UpliFT-D Trial On PBFT02markets.businessinsider.com - December 20 at 9:47 AMPassage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Prioritiesfinance.yahoo.com - December 20 at 9:47 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcumen PharmaceuticalsNASDAQ:ABOSAcumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.CellectisNASDAQ:CLLSCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.DBV TechnologiesNASDAQ:DBVTDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.MeiraGTxNASDAQ:MGTXMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Passage BioNASDAQ:PASGPassage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.